1. Introduction {#s0005}
===============

Hydrogen peroxide (H~2~O~2~) is both a chemical toxicant and at lower concentrations an endogenous physiological signaling molecule [@bb0005]. Intracellular concentrations can manifest thresholds that determine the precise nature of the signal. However, the transmission of the signaling events generally occurs through the oxidation of cellular nucleophiles, particularly susceptible cysteine residues that can be found in certain clusters of target proteins [@bb0010]. Emerging evidence confirms that cellular sensing of redox changes is mediated through post-translational modifications (PTMs) of cysteine residues. While there is debate as to what constitutes redox "sensing" versus redox "signaling" [@bb0015], cysteine residues at various oxidation states are at the center of the process. Cysteine is one of the least coded amino acids in the human genome (\~ 200,000), implying restricted usage, but evolutionary importance [@bb0020]. *S*-glutathionylation is a PTM that occurs when a cysteine in a low pK environment forms a disulfide bond with glutathione (GSH) [@bb0025], [@bb0200]. *S*-glutathionylation is a dynamic and reversible cycle that can serve as a secondary level of regulation for a number of important cellular processes in protein cluster functionalities including, kinases and phosphatases; glycolytic enzymes; calcium transport proteins; cytoskeletal structural proteins; protein folding pathways; transcription factors [@bb0035]. *S*-glutathionylation introduces a negative charge and frequently alters tertiary and quaternary structure and a variety of protein--protein interactions [@bb0010], [@bb0200]. *S*-glutathionylation can serve to protect against further oxidative damage and reversal can restore the protein to its native state [@bb0025], [@bb0035], a circumstance well suited to redox-mediated regulatory control.

Direct exposure to H~2~O~2~ can occur through the use of oral hygiene and cosmetic tooth whiteners, and commercially available products can contain concentrations that range from 0.1 to 6.0%. Various reports have outlined adverse health risks associated with localized effects of increased cell exposure to reactive oxygen species (ROS; [@bb0040], [@bb0045]). For example, DNA damage in buccal mucosa cells has been associated with etiology of oral cancers and suggested as a biomarker to assess exposure to oxidative stress or environmental toxins [@bb0050]. Indirect exposure to H~2~O~2~ can occur as a consequence of metabolism of a wide range of drugs that have electrophilic centers. This is particularly relevant for a number of anticancer drugs and irradiation.

Recent trends in oncology drug development have moved towards targeted therapies that allow optimizing treatment for specific groups of cancer patients. The application of biomarkers that predict therapy efficacy and/or toxicity for individual patients and malignancies would reduce incidence of ineffective treatment protocols and unnecessary side effects, as well as optimize effective treatments. In diagnosis or prognosis of specific diseases, assessments of matrix combinations of proteins, nucleic acids or metabolites may in some cases provide the best correlations. However, in measuring drug response, a focused biomarker can lend itself to quantitative measurements through dose--response studies. Preclinical studies in mice have suggested that *S*-glutathionylated serine protease inhibitors (serpins A1 and A3) in blood could be used as correlates to drug exposure [@bb0055]. Extension of these data to humans suggested that the evaluation of *S*-glutathionylated protein profiles in plasma when animals are exposed to agents that cause ROS may provide useful biomarkers [@bb0055]. Collection and monitoring of buccal cells provides a relatively non-invasive technique to monitor biomarkers that may assess systemic impact of drug or xenobiotic exposure. It is challenging to obtain sequential biopsy samples from patients with solid tumors and as such, surrogate tissues especially blood or cheek (buccal) cells can provide practical alternatives. To this end we enacted a clinical trial to consider the predictive value of measuring *S*-glutathionylated proteins from buccal cell samples taken from normal volunteers exposed to H~2~O~2~ containing mouthwash. This approach may prove applicable to pharmacodynamic studies that involve other drugs or radiation.

2. Participants and methods {#s0020}
===========================

2.1. Participants {#s0025}
-----------------

Eighteen healthy adult (18--75 years old), English-speaking, non-cognitively impaired volunteers, representative of all races and genders were recruited at the Medical University of South Carolina between October 2012 and June 2013. Subjects provided written informed consent and self reported data on sex, age, race, smoking, dental procedures, and alcohol consumption are summarized in [Table 1](#t0005){ref-type="table"}.

2.2. Buccal cell collection {#s0030}
---------------------------

The study protocol ([Fig. 1](#f0005){ref-type="fig"}) was designed to evaluate the induction of *S*-glutathionylation and recovery associated with both acute and chronic ROS exposure. Since thiol homeostasis in mammals may be subject to diurnal variations [@bb0060], buccal cells were collected between 10 and 11 a.m. to limit inconsistencies that may be associated to variations in sensitivity to oxidative stress. Our estimates suggest that, contingent upon the extent of the ROS exposure (time and concentration effects), the half-life of *S*-glutathionylation approximates 3--6 h [@bb0065]. This formed part of the rationale for the timing of sample collection. Because the *S*-glutathionylation cycle has a reversible component, longer term samples to assess the degree of de-glutathionylation were incorporated [@bb0010], [@bb0205].

Prior to collection participants pre-rinsed the oral cavity with 20 mL deionized (dH~2~O) water for 2 min, followed by a 1--5 min exposure to (a) 10 mL dH~2~O or (b) 10 mL H~2~O~2~ (442 mM; 1.5% H~2~O~2~) containing commercial mouthwash (Colgate, New York, USA). Participants brushed both cheeks vigorously using 20 strokes with a sterile toothbrush followed by two-2 min rinses (10 mL dH~2~O). Rinses were collected in 50 mL tubes and washes were combined and labeled as Wash 1 (W1). After a 'recovery period' of 15--30 min 2 washes were repeated using a new sterile toothbrush, labeled as Wash 2 (W2). Toothbrushes were rinsed in their respective washes to recover any further buccal cells. Complete turnover of buccal epithelium occurs within 5--7 days [@bb0075]. Between all control (collected on Day 1 (D1)) and treatment protocols (initiating on Day 7 (D7)) a waiting period of 6 days allowed recovery and avoided bias towards collection of differentially oxidized cell populations (cell surface vs. underlying cells) [@bb0050], [@bb0075].

In extended exposure protocols, following an initial buccal cell collection (rinsing with dH~2~O (Day 1-Wash 1 (D1-W1) and Day 1-Wash 2 (D1-W2))), participants waited 6 days for epithelium recovery and then began an exposure protocol of two H~2~O~2~ mouthwash washes/day for 2 min. H~2~O~2~ rinses were performed between 10--11 AM and 9--10 PM. Buccal cells were collected following each H~2~O~2~ exposure, with a recovery period of 30 min between W1 and W2. Participants continued this protocol for 4 days (D7--10) with collections from alternating cheeks each day ([Fig. 1](#f0005){ref-type="fig"}).

Buccal cells were centrifuged (800 × *g* for 5 min at 4 °C) and washed three times (chilled 1× PBS), and the cell pellets were flash frozen and stored at  − 80 °C. Unless subject to freeze thawing (not used in this protocol), our previous experiences suggest that *S*-glutathionylated proteins are stable at − 80 °C for \> 2 years. This has been confirmed by others [@bb0080].

2.3. Cell culture {#s0035}
-----------------

The human buccal cell line, TR146 (Sigma-Aldrich, St. Louis, USA) was maintained at 37 °C and 5% CO~2~/95% air in 98% humidity, in DMEM supplemented with 10% FCS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. To mimic the growth of cells in the oral cavity, 24,000 cells/cm^2^ were cultured on Falcon® 4.2 cm^2^ permeable polyethylene terephthalate inserts with a pore size of 0.4 μm (Corning, MA, USA) for 7 days prior to oxidative stress studies. Cells were rinsed twice with 1 × PBS prior to H~2~O~2~ and 'recovery periods' were in the presence of growth medium.

2.4. Protein preparation {#s0040}
------------------------

Cell pellets were suspended in lysis buffer (20 mM Tris--HCl, pH 7.5, 15 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, and 1 mM β-glycerophosphate with freshly added protease and phosphatase inhibitors, 5 mM NaF and 1 mM Na~3~VO~4~) and incubated for 30 min on ice. Lysates were sonicated for 10 s and centrifuged for 30 min at 10,000 *g* at 4 °C. Protein concentrations were assayed with Bradford reagent (Bio-Rad Laboratories, Hercules, CA) using IgG as a standard.

2.5. Immunoblot analysis {#s0045}
------------------------

Equal amounts of total protein were electrophoretically resolved under non-reducing conditions on 10% SDS-polyacrylamide gels (SDS-PAGE); unmodified proteins were separated under reducing conditions. Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA). Non-specific binding was reduced in blocking buffer (20 mM Tris--HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20, 1 μM protease inhibitors, 5 mM NaF, and 1 mM Na~3~VO~4~) containing 10% non-fat dried milk, for 1 h. Membranes were incubated with monoclonal anti-glutathione antibodies (Virogen, Watertown, MA) to detect protein *S*-glutathionylation (PSSG), or polyclonal antibodies for actin or ATF3 (Abcam, Cambridge, MA) in blocking buffer containing 5% non-fat dried milk overnight at 4 °C, washed 3× with PBS for 15 min, and incubated with the appropriate secondary antibody (Amersham Biosciences, Piscataway, NJ) conjugated to horseradish peroxidase for 1 h. Membranes were washed 3 × and developed with enhanced chemiluminescence detection reagents (Bio-Rad). Blots were scanned with a BioRad ChemiDoc system and visualized with a transilluminator and evaluated using Quantity One software (version 4.5.2; Bio-Rad) and normalized to actin.

2.6. Immunoprecipitation and identification of *S*-glutathionylated proteins {#s0050}
----------------------------------------------------------------------------

Immunoprecipitations of *S*-glutathionylated proteins were performed using the anti-glutathione antibody as previously described [@bb0055]. Human buccal cell samples (2 mg) were incubated overnight at 4 °C with 5 μg of the antibody and separated by non-reducing SDS-PAGE and bands corresponding to *S*-glutathionylated proteins were excised, trypsin digested and analyzed by matrix-assisted laser desorption/ionization, time-of-flight (MALDI-TOF) mass spectrometry at the Proteomics Core Facility of the Medical University of South Carolina. Protein identification was performed using software from the National Center for Biotechnology Information protein database. Automated database searching was performed with BioWorks software running TurboSequest. Accuracy of the peptide assignments was assessed with Peptide prophet and Protein prophet algorithms from the Institute for Systems Biology (Seattle, WA). Automated database searching used GPS Explorer software using Mascot. Only peptides and proteins with a reported confidence \> 95% were considered identified.

2.7. Cell viability and DNA damage evaluation {#s0055}
---------------------------------------------

TR146 cell viability was evaluated using Trypan Blue solution (Sigma-Aldrich) and assessing the number of live (translucent) and dead (blue) cells using a hemocytometer under phase-contrast microscopy. DNA damage was evaluated using OxiSelect Oxidative DNA ELISA kit (Cell BioLabs, San Diego, CA) in an ELISA format based on comparison to a predetermined 8-OHdG standard curve.

2.8. RNA collection and qPCR analyses {#s0060}
-------------------------------------

Frozen buccal cell pellets were resuspended in 250 μL TE Buffer (10 mM Tris--HCl, pH 8.0, 10 mM EDTA) containing 200 mM NaOH and 1% SDS. Pellets were then incubated for 5 min at room temperature and then 250 μL 3 M potassium acetate, pH 5.5 was added for an additional 5 min at 4 °C. The supernatant was collected by centrifuging at 18,000 *g* for 10 min and the RNA processed using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and stored at − 80 °C for future analyses. cDNA was generated from 2 μg total RNA and real-time PCR (qPCR) reactions and data analyses were performed using iQ SYBR Green Supermix and the MyiQ thermal cycler (Bio-Rad, Hercules, CA) (40 cycles, 58 °C annealing, 81 °C real-time data collection). Each oligonucleotide primer was synthesized by OriGene (Rockville, MD). Results of experiments were verified by repetition of RT-PCR with RNA extracted from different aliquots of cells (at least three independent reactions performed per template/primer combination). For relative quantification in qPCR, a mathematical model was used that incorporated the effects of the efficiency of amplification for each primer pair over a 10^4^ range of template dilutions and starting template concentrations were normalized by comparing to β-actin amplification. qPCR reactions were run in triplicate for each sample, and at least three independent experiments were performed. Overall results were mean of results from eight individuals\' samples.

2.9. Statistical analyses {#s0065}
-------------------------

Statistical analyses were performed in Prism version 5.0 (GraphPad Software, Inc., San Diego, CA). p values lower than 0.05 were considered significant. Differences in the induction of total *S*-glutathionylation and ATF3 proteins from participants and cell culture following control or H~2~O~2~ exposure were analyzed by analysis of variance (ANOVA) followed by a Bonferroni\'s multiple comparison post-hoc test. For the induction of *S*-glutathionylation over time and with increasing doses in buccal cells in vivo and in TR146 cells, a Dunnett\'s multiple comparison post hoc test against baseline controls was used (S1-W1 or 0 H~2~O~2~, no recovery). The induction of 8-OHdG in buccal cells following treatment with H~2~O~2~ was analyzed by ANOVA with a Dunnett\'s multiple comparison post-hoc test against baseline control (S1-W1). Corrections were applied based on program recommendations.

3. Results {#s0010}
==========

Oral exposure to 1.5% H~2~O~2~ rapidly led to a significant increase in *S*-glutathionylation of numerous proteins from human buccal samples relative to the individual baseline untreated control samples (p \< 0.0001, [Fig. 2](#f0010){ref-type="fig"}A--B). *S*-glutathionylation levels decreased significantly (p \< 0.01) after 15 min, but did not return to baseline (p \< 0.0001). There were no significant differences in protein *S*-glutathionylation levels between initial and recovery samples collected in the control and baseline samples ([Fig. 2](#f0010){ref-type="fig"}B). The sensitivity of the antibodies and the conditions utilized in the development of the blots likely minimized detection of *S*-glutathionylated proteins that were in low abundance. This likely underestimates the basal level of post-translationally modified proteins in samples not exposed to H~2~O~2~, but these levels are usually quite low. Basal levels of *S*-glutathionylation are also dependent on cell and tissue type. However, a \~ 40 kDa protein identified as actin, commonly found to be *S*-glutathionylated in the absence of external ROS [@bb0010] was present in baseline samples. Accompanying immunoblots showed significant increases in protein levels of the oxidative stress-responsive transcription factor ATF3 in buccal cells collected 15 min after H~2~O~2~ (p \< 0.001) ([Fig. 2](#f0010){ref-type="fig"}A--B), confirming that H~2~O~2~ activated a general stress associated transcription factor. Real-time qPCR ([Fig. 2](#f0010){ref-type="fig"}C) confirmed that ATF3 was also transcriptionally upregulated.

*S*-glutathionylated proteins identified by MALDI-TOF mass spectrometry ([Table 2](#t0010){ref-type="table"}) fell into three functional clusters: (a) redox regulatable enzymes. For example, activities of GSTP1 [@bb0205] and various cysteine dependent serine protease inhibitors [@bb0055] have been shown to be impacted by *S*-glutathionylation. Inter-α-trypsin inhibitor is one example of this family [@bb0085], but until now there has been no indication that it is subject to *S*-glutathionylation. (b) A group of structural proteins influencing cell shape and motility, also typically subject to redox regulation [@bb0025]. (c) Lactotransferrin, complement and albumin are cysteine rich proteins known to be subject to this PTM [@bb0055]. Given the sensitivity restrictions of the antibody pull down and detection methodologies used, it is possible that some less abundant proteins were not identified. These proteins represent those that are in *S*-glutathionylated at high levels and thus readily detected. Moreover, while additional peptide fragments were found, the algorithms used in the proteomic detection procedures prevent identification of false positives.

The *S*-glutathionylation response was evaluated following chronic exposure outlined in [Fig. 1](#f0005){ref-type="fig"}. Data show that twice daily exposure for 4 days significantly potentiated the induction of *S*-glutathionylation in buccal cells ([Fig. 3](#f0015){ref-type="fig"}A--B) (p \< 0.001) as compared to participants\' baseline control samples (D1-W1), in addition to sustaining the time periods that cells take to recover to basal levels (p \< 0.01 at D8 in W2 and p \< 0.001 at D9 and D10 in W2, compared to D1-W1).

As a correlative biomarker of oxidative stress, levels of 8-OHdG were measured in the human buccal samples exposed to the chronic H~2~O~2~ time course ([Fig. 4](#f0020){ref-type="fig"}). In participants completing an extended repeat-exposure protocol, H~2~O~2~ exposure significantly increased 8-OHdG levels by the second day as compared to the participants\' baseline control (D1-W1) samples (p \< 0.001). Significantly elevated levels of the damaged DNA markers were maintained throughout the remainder of the study (through protocol Day 10) in both initial and recovery (after 30 min) samples compared to baseline control (D1-W1) (p \< 0.001).

TR146 is an immortalized human buccal cell line (isolated from a neck metastasis) forming undifferentiated, non-keratinized, stratified epithelium that shares many morphological and functional characteristics of normal oral mucosa [@bb0090], [@bb0095]. TR146 cells were exposed to increasing concentrations of H~2~O~2~ for 2.5 min (concentrations of \> 5% resulted in significant cell death). Immunoblot analyses showed that higher H~2~O~2~ concentrations significantly increased total protein *S*-glutathionylation levels compared to untreated controls (1% p \< 0.5; 2%--5% p \< 0.001; [Fig. 5](#f0025){ref-type="fig"}A--B). This dose--response plateaus at \~ 4% H~2~O~2~, likely due to saturation or cytotoxicity. Following a 15 min recovery, significantly elevated levels of *S*-glutathionylated proteins remained in all treated samples compared to untreated controls (1% p \< 0.5; 2%--5% p \< 0.001). Analyses of *S*-glutathionylation levels in matched samples (immediately following H~2~O~2~ exposure compared to after 15 min recovery) showed that recovery (as a result of deglutathionylation) had not occurred by 15 min (p \> 0.05) and there was a negative correlation with H~2~O~2~ dosage ([Fig. 5](#f0025){ref-type="fig"}B). A prominent band corresponding to *S*-glutathionylated actin was detected in untreated samples, supportive that the cell model mimics that of the human data ([Fig. 5](#f0025){ref-type="fig"}A).

Treatment of TR146 cells with 1.5% H~2~O~2~ yielded a time-dependent increase in *S*-glutathionylation that became saturated by 5 min (1 and 2.5 min p \< 0.05; 5 and 10 min p \< 0.001) as compared to untreated controls. Following 15 min recovery *S*-glutathionylation levels were maintained in cells that had been exposed to 1.5% H~2~O~2~ (2.5 min p \< 0.05; 5 min p \< 0.01; 10 min p \< 0.001). Comparison of protein *S*-glutathionylation levels in matched samples (immediately following H~2~O~2~ exposure compared to after 15 min recovery) showed that significant deglutathionylation had not occurred by 15 min (p \> 0.05). Extended exposures to H~2~O~2~ mildly increased recovery to baseline *S*-glutathionylation levels ([Fig. 6](#f0030){ref-type="fig"}A). Treatment of cells with cisplatin did not induce direct *S*-glutathionylation ([Fig. 6](#f0030){ref-type="fig"}B). However, treatment of TR146 cells with 2.43 μM cisplatin for 48 h (IC~50~) potentiated total levels of (and sustained) *S*-glutathionylation following H~2~O~2~ (p \< 0.001) compared to untreated controls. This combination also caused saturation of *S*-glutathionylation levels within a min, which was further sustained and less reversible ([Fig. 6](#f0030){ref-type="fig"}A--B). Analyses of matched samples (immediately following H~2~O~2~ compared to 15 min recovery) showed that only low levels of *S*-glutathionylation had occurred by 15 min with 1.5% H~2~O~2~ for 2.5, 5 and 10 min (p \> 0.05). Cells exposed to 1.5% H~2~O~2~ for 1 min showed significant *S*-glutathionylation levels during the 15 min recovery period (p \< 0.05) [Fig. 6](#f0030){ref-type="fig"}B.

4. Discussion {#s0015}
=============

Aerobic metabolism is the most efficient way to create energy, however, reactive oxygen species (ROS) such as superoxide (O~2~^•−^) and hydroxyl radicals (^•^OH) are byproducts that are non-specifically reactive with cellular nucleophiles and can cause toxicity. Exogenous hydrogen peroxide can be a precursor of these, but it is generally stable (t~1/2~, months), can move freely within and between cells and has evolved as an endogenous second messenger, frequently signaling through redox regulation of reactive cysteine residues in target proteins [@bb0100]. Reversible *S*-glutathionylation of cysteines provides a framework for a cycle that facilitates such regulation [@bb0025]. The biological effects of H~2~O~2~ are concentration dependent with a threshold effect that influences response. The present study was designed as an exploratory clinical trial to consider whether protein *S*-glutathionylation might be adaptable as a quantitative/qualitative measure of H~2~O~2~ (ROS) exposure. Extrapolating these results may lead to incorporation of similar biomarkers into other protocols to monitor pharmacokinetic/dynamic measurements of other drugs that produce ROS.

The importance of salivary oxidant state has been considered in oral inflammatory diseases and cancer etiology [@bb0105]. However, there have been no studies investigating the impact of ROS on PTM of proteins from buccal cells. In the present trial, the use of the H~2~O~2~ mouthwash rapidly induced both a time- and dose-dependent increase in protein *S*-glutathionylation that remained for extended periods. Chronic H~2~O~2~ both potentiated induction of *S*-glutathionylation and extended the period of recovery (deglutathionylation). In these samples, H~2~O~2~ also enhanced expression of ATF3, a transcription factor specifically linked with ROS stress response pathways [@bb0110]. In addition, H~2~O~2~ characteristically causes nucleic acid damage [@bb0115] and our data confirm a dose/time response for the presence of 8-OHdG in buccal cell samples. Establishing whether these levels of DNA damage cause precancerous dysplasia, leukoplakia or oral cancer was beyond the scope of this study. Previous multi-center, case-controlled studies have reported a link between daily mouthwash use and head and neck or esophageal cancers; however, these reports did not consider the relevance of ROS on cell events [@bb0120]. H~2~O~2~ containing bleaching products have also been associated with genotoxic effects including micronuclei formation and DNA damage in buccal mucosa. These have been suggested as biomarkers to assess ROS exposure or genetic damage in chemoprevention trials [@bb0050], [@bb0125], [@bb0130], [@bb0135]. However, levels of DNA damage may not always be high enough to provide a reliable marker for this type of exposure. In the present trial, our data support linkage between protein *S*-glutathionylation and DNA damage in buccal cells.

Proteomic analysis of buccal cell protein *S*-glutathionylation following H~2~O~2~ revealed some previously characterized, but a number that are novel. For example, GSTP1 has been implicated in cancer etiology, drug resistance, and kinase signaling and can carry out the forward reaction in the *S*-glutathionylation cycle [@bb0210]. Its activity is subject to auto-regulation by *S*-glutathionylation at cysteines 47 and 101 [@bb0205]. Previously, altered GST expression was linked with differentiation and tumor stage in buccal mucosal cancers [@bb0145], [@bb0150], implying a plausible link with *S*-glutathionylation. *S*-glutathionylated plasma protease inhibitors (serpins A1 and A3), similar to inter-α trypsin inhibitor, not only regulate mobilization of bone marrow progenitor cells [@bb0155], [@bb0160] but also act as serum biomarkers for exposure to ROS [@bb0055]. Specific protein clusters are susceptible to *S*-glutathionylation [@bb0010], [@bb0025] and those identified here can be classified accordingly. For example, structural (B4GALNT2, GRAF, PAR6, Flaggrin-2, Plakoglobin, Reticulon-2, actin, histone H1), or for lactotransferrin, complement and albumin, cysteine rich blood proteins that are sensitive to redox. One (or more) of these *S*-glutathionylated proteins may progress as a plausible biomarker for exposure to H~2~O~2~ or other ROS. The antibody pull-down techniques used in this study have some limitations, particularly with regard to sensitivity (for example, antibody detection can vary depending on the conformation of the glutathione adduct and the environment of the thiolated cysteine) and may have limited the number of *S*-glutathionylated proteins identified. Nevertheless, those proteins shown in [Table 2](#t0010){ref-type="table"} represent primary *S*-glutathionylation targets.

In general terms, buccal cells provide an accessible pool of epithelial cells that can mirror systemic health status, whether influenced by exposure to ROS [@bb0165] or environmentally genotoxic agents [@bb0215], [@bb0175]. Deleterious effects of chemotherapy and radiation can directly manifest in the oral mucosa, frequently producing compromised epithelial proliferation and mucosal ulceration [@bb0220]. Because a large part of the highly vascularized mucosa is non-keratinized, exposure of the oral mucosa to redox altering agents may also leave deeper tissues at risk. Protein *S*-glutathionylation is induced in rats, where high levels of protein bound GSH were detected in squamous cell carcinomas of the tongue and adjacent tissues [@bb0185]. Significant levels of *S*-glutathionylated proteins were present in the oral cavity long before the presence of clinically observable lesions implying that they may serve in the determination of cancer susceptibility and early etiology.

In parallel with the human clinical trial, we analyzed the effects of H~2~O~2~ in a transformed human buccal cell line. TR146 cells have characteristically high levels of expression of GSTP (data not shown). Induced and sustained levels of *S*-glutathionylation in TR146 cells were similar to those in human buccal cell samples. We compared the results with cells exposed to cisplatin, a drug known to cause damage to both nucleic acids and proteins [@bb0190]. While cisplatin did not cause significant *S*-glutathionylation, in combination with H~2~O~2~, the drug combination potentiated it and delayed deglutathionylation. Since the platinum alkylating species [@bb0195] do not cause the PTM, some selective degree of electrophilic selectivity is required.

In the present study, the *S*-glutathionylation profile of proteins from buccal cells is predictive of exposure to H~2~O~2~. As such, buccal cell samples should be useful as a surrogate tissue source for biomarker analysis to define the effects of specific drugs that can cause ROS, enabling development of candidate biomarkers of response to redox-altering therapeutics. Furthermore, persistent levels of ROS may activate pro-inflammatory events causing toxicity. The identification of biomarkers that evaluate the effects of ROS in the oral cavity may define at-risk populations for oral cancer and be useful in clinical trials to measure the efficacy or toxicity of drugs that influence redox homeostasis. Current efforts validating the prognostic potential of protein *S*-glutathionylation profiles in large cohorts of patients are currently underway.

![Protocol study design.](gr1){#f0005}

![H~2~O~2~ induces protein *S*-glutathionylation of human buccal cells through stress response pathways.\
Buccal cells were collected following 5 min oral rinses with dH~2~0 (D1-W1). After a recovery period of 15 min, buccal cells were collected in an additional dH~2~0 wash (D1-W2). After 6 days buccal cells were similarly collected from the same participant following 5 min oral rinses with a mouthwash containing 1.5% H~2~O~2~ (D7-W1 and D7-W2). Buccal cell pellets were lysed and 40 μg protein was loaded and evaluated by immunoblot for *S*-glutathionylation (PSSG) or ATF3 levels. Actin levels were used as loading controls. Representative blots from two participants are shown (panel A). Averaged values and statistical comparisons are shown in panel B, where fold change is calculated relative to D1-W1. D = day; W = wash; NS = not significant; \*\* = p \< 0.01; \*\*\* = p \< 0.001; \*\*\*\* = p \< 0.0001; n = 3, ± SD. Panel C shows the qPCR results for ATF3 samples prepared from eight individuals.](gr2){#f0010}

![H~2~O~2~ mediated protein *S*-glutathionylation and recovery from human buccal cells.\
H~2~O~2~ induced protein *S*-glutathionylation and recovery in human buccal cells is dose dependent. Buccal cells were collected following oral rinses for 2 min with dH~2~0 (D1-W1). After a recovery period of 30 min, buccal cells were collected in an additional dH~2~0 wash (D1-W2). Repeat H~2~O~2~ exposure protocols were initiated 6 days later to allow for oral epithelium recovery. Beginning on Day 7, 2 min 1.5% H~2~O~2~ treatments were conducted twice daily (in the AM and PM) to represent habitual mouthwash usage. All samples were collected from each participant daily in the morning immediately following treatments (D7-W1; D8-W1; D9-W1; D10-W1) and then again 30 min after exposure (D7-W2; D8-W2; D9-W2; D10-W2). Buccal cell pellets were lysed, and 40 μg total protein was loaded and total protein *S*-glutathionylation (PSSG) levels evaluated by immunoblots (a representative immunoblot from a participant is shown in Panel A). Densitometry levels from all participants were normalized to actin and averaged values and statistical comparisons are shown in panel B, where fold change is calculated relative to D1-W1. D = day; W = wash; \*\* = p \< 0.01; \*\*\* = p \< 0.001; n = 11, ± SD.](gr3){#f0015}

![H~2~O~2~ induced DNA damage in human buccal cell samples estimated using 8-OHdG as a marker.\
Buccal cells were collected following oral rinses for 2 min with dH~2~0 (D1-W1). After a recovery period of 30 min, buccal cells were collected in an additional dH~2~0 wash (D1-W2). To allow for oral epithelial recovery, repeat H~2~O~2~ exposure protocols were initiated 6 days later. Beginning on Day 7, 2 min 1.5% H~2~O~2~ treatments were conducted twice daily (in the AM and PM) to represent habitual mouthwash usage. All samples were collected from each participant daily in the morning immediately following treatment (D7-W1; D8-W1; D9-W1; D10-W1) and then again 30 min after exposure (D7-W2; D8-W2; D9-W2; D10-W2). 8-OHdG levels were calculated against a standard curve. D = day; W = wash; \*\*\* = p \< 0.001; n = 3, ± SD.](gr4){#f0020}

![H~2~O~2~ mediated protein *S*-glutathionylation in TR146 cells is concentration dependent.\
TR146 cells grown in transwells were treated with various concentrations of H~2~O~2~ followed by removal and a recovery period of 15 min. Panel A shows a representative *S*-glutathionylation (PSSG) immunoblot. Densitometry levels were normalized to actin and averaged values and statistical comparisons are shown in panel B, where fold change is calculated relative to no H~2~O~2~. Statistical comparisons of H~2~O~2~ induced *S*-glutathionylation levels compared to baseline untreated control samples (0% no recovery), as well as between matched treatments pre- and post-15 min recovery are shown. NS = not significant; \* = p \< 0.05; \*\*\* = p \< 0.001; n = 3, ± SD.](gr5){#f0025}

![H~2~O~2~ induced protein *S*-glutathionylation in TR146 cells in buccal cells is time-dependent and cisplatin pretreatment potentiates and sustains *S*-glutathionylation levels.\
TR146 cells grown in transwells were treated with 1.5% H~2~O~2~ for various time periods followed by removal and a recovery period of 15 min without any pretreatment (panel A) or with cell pretreatment for 48 h with 2.43 μM cisplatin (panel B). Representative *S*-glutathionylation (PSSG) immunoblots are shown in the upper panels. Densitometry levels were normalized to actin and averaged values and statistical comparisons are shown graphically in the bottom of panels A and B, where fold change is calculated relative to untreated (0 min) cells. Statistical comparisons of H~2~O~2~ induced *S*-glutathionylation levels as compared to baseline untreated control samples (0 min, no recovery), as well as between matched treatments pre- and post-15 min recovery are shown. NS = not significant; \* = p \< 0.05; \*\* = p \< 0.01; \*\*\* = p \< 0.001; ∝ = p \< 0.05 where significant deglutathionylation occurred after a 15 min recovery period in cells treated for 1 min with 1.5% H~2~O~2~; n = 4, ± SD.](gr6){#f0030}

###### 

Demographic characteristics of participants.

  Demographic variable                                                            Number in each category (%) (n = 18)
  ------------------------------------------------------------------------------- --------------------------------------
  Age                                                                             
   Mean (SD)                                                                      30.9 (13.3)
   18 to 30 years                                                                 10 (56%)
   31 to 65 years                                                                 8 (44%)
  Gender                                                                          
   Female                                                                         14 (78%)
   Male                                                                           4 (22%)
  Ethnicity                                                                       
   White                                                                          11 (62%)
   Black                                                                          1 (5%)
   Native American                                                                1 (5%)
   Hispanic                                                                       2 (11%)
   Asian                                                                          3 (17%)
  Overall health status[a](#tf0005){ref-type="table-fn"}                          
   High = excellent or very good                                                  7 (39%)
   Medium = good                                                                  10 (56%)
   Low = fair or poor                                                             0 (0%)
  Alcohol consumption[a](#tf0005){ref-type="table-fn"}                            
   No                                                                             6 (33%)
   Occasionally (not consistently)                                                2 (11%)
   1 to 5 drinks/week                                                             6 (33%)
   5 to 10 drinks/week                                                            3 (17%)
   More than 10 drinks/week                                                       0 (0%)
  Smoking habits[a](#tf0005){ref-type="table-fn"}                                 
   No                                                                             17 (100%)
   Yes                                                                            0 (0%)
  Mouthwash usage[a](#tf0005){ref-type="table-fn"}                                
   No                                                                             8 (44%)
   1 to 3 times/day                                                               8 (44%)
   More than 4 times/day                                                          1 (5%)
  Currently taking medications[a](#tf0005){ref-type="table-fn"}                   
   No                                                                             11 (61%)
   Yes                                                                            6 (33%)
  Currently taking vitamins[a](#tf0005){ref-type="table-fn"}                      
   No                                                                             11 (61%)
   Yes                                                                            6 (33%)
  Recent dental procedures (within last month)[a](#tf0005){ref-type="table-fn"}   
   No                                                                             16 (89%)
   Yes                                                                            1 (5%) cleaning

One volunteer declined to answer.

###### 

MALDI-TOF identification of *S*-glutathionylated buccal cell proteins following H~2~O~2~ exposure.

  Protein                     MW (kDa)     Protein function
  --------------------------- ------------ ---------------------------------------------------------------------------------------------------------------------
  GSTP1                       24           Phase II metabolism; *S*-glutathionylation.
  Inter-α trypsin inhibitor   75           Plasma protease inhibitor.
                                           
  B4GALNT2                    20           β-1,4-N-acetyl-galactosaminyl transferase 2 isoform c; protein glycosylation; negative regulation of cell adhesion.
  GRAF                        52           rho GTPase activating protein 26; associates with focal adhesion kinase.
  PAR6                        65           Partitioning defective 6 homolog γ; cell division and polarization.
  Flaggrin                    125          Epithelial structure; mucosal S100 fusion type protein.
  Plakoglobin                 125          γ-Catenin; complexes with cadherins.
  Reticulon-2                 65, 20       ER protein promotes membrane curvature, nuclear pore complex and vesicle formation.
  Actin                       42           Microfilament formation.
  Histone H1                  20           Chromatin structure.
                                           
  Lactotransferrin            65           Antimicrobial activity; part of the innate defense at the mucoses.
  Complement                  52, 42       Innate immunity.
  Albumin                     75, 65, 42   Blood globular protein.
